首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1410089

家庭輸液治療市場：2023年至2028年預測

Home Infusion Therapy Market - Forecasts from 2023 to 2028

出版日期: 2023年12月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2021年全球家庭輸液治療市場規模為327.81億美元。

預計家庭輸液治療市場將在整個預測期內穩定成長。家庭輸液只是通常作為門診手術在家中向患者提供的眾多藥物治療之一。大多數這些藥物必須透過針頭或導管輸送，這個過程稱為輸注。與家庭輸液治療相關的多重好處和增加的不動障礙是家庭輸液治療市場的主要成長動力。此外，不斷上升的醫院感染率和鼓勵家庭治療的政府法規預計將進一步推動家庭輸液治療市場。

家庭輸液治療的多種相關益處

居家輸液治療為患者帶來了廣泛的好處，從而促進了家庭輸液治療的採用並促進了家庭輸液治療市場的發展。患者對居家輸液治療的滿意度很高，研究表明，在家病患比住院病患有更好的臨床結果。根據您的個人醫療保健計劃，它可能比在醫院或診所獲得相同的服務便宜。此外，Evernorth Health Services 發現 78% 的客戶表示，他們「非常」或「有些」願意採用其他類型的護理，例如讓臨床醫生上門服務。近年來，對更多服務的需求不斷增加護理方法方面的靈活性和選擇。據信，患者對居家照護的傾向以及相關的好處將推動家庭輸液治療市場的發展。

行動障礙增加

限制身體活動的不動障礙病例數量不斷增加，顯示對家庭輸液治療的需求不斷成長。例如，有13億重度身障者。根據世界衛生組織 2023 年 3 月發布的最新資訊，這相當於我們六分之一的人，即世界人口的 16%。據世界衛生組織稱，殘障人士找到方便且負擔得起的交通途徑的難度是正常人的 15 倍。因此，這些行動障礙預計將對家庭輸液治療市場產生積極影響，因為它為患者提供了便利的家庭環境。

需要縮短住院時間

居家輸液治療有助於縮短住院時間。據世界衛生組織稱，每 100 名急診醫院患者中，高所得國家有 7 名患者，中低收入國家有 15 名患者在住院期間預計會感染至少 1 例醫療保健相關感染疾病(HAI)。。平均每 10 名受影響者就會死於 HAI。世界衛生組織 2022 年的一項研究發現，超過一半的伴有器官衰竭的膿毒症病例在成人加護病房接受治療，並且在醫院接受治療的膿毒症患者中約有四分之一與醫療保健有關。據透露。這種醫院感染帶來了問題，並正在推動家庭輸液治療市場的採用。

市場機會

上述成長動力顯示家庭輸液治療市場存在巨大機會。此外，政府法規也為居家輸液治療市場創造了成長機會。例如，2021 年，醫療保險和醫療補助服務中心 (CMS) 通過了新法規，擴大了家庭輸液治療的覆蓋範圍，除了治療本身之外，還涵蓋各種相關的護理和監測服務。此外，Eitan Medical 還推出了 Avoset(TM)，這是一種最連網型的連接輸液多療法門診輸液系統，正在徹底改變急性後護理和專業輸液治療。此外，家庭輸液治療的監管核准將進一步推動家庭輸液治療市場並提供進入機會。例如，抗癌藥物家庭注射療法於2020年6月獲得ASCO董事會核准。

市場抑制因素

有幾個複雜的因素可能會限制家庭輸液治療市場。例如，家庭輸液藥局、患者、醫生、出院計劃人員、健康保險和其他相關人員必須密切合作才能完成這個過程，因為它可能是一個複雜的生態系統。由於相關人員眾多，斷開連接的資料可能會帶來嚴重問題，並導致各種規定、管理和/或編碼問題。例如，醫生通常會提交事先核准請求和處方申請，這些請求和處方索賠是單獨透過計劃的。

預計北美將大幅成長

預計在預測期內，北美地區將在家庭輸液治療市場中佔據重要佔有率。造成這一佔有率的因素包括鼓勵家庭輸液治療的有利政府法規，以及不活動的增加、癌症等慢性疾病和人口老化。例如，12.1% 的美國成年人患有行動障礙，導致行走或爬樓梯變得極其困難，而最近的 CDC資料顯示，12.8% 的美國成年人在集中註意力、記憶或做決定方面存在明顯困難。此外，Baxter 和 Braun Melsungen AG 等市場參與者預計將進一步推動該地區的家庭輸液治療市場。

家庭輸液治療市場參與者

百特國際是一家總部位於美國的醫療保健公司，提供急性、營養、腎臟、醫院和外科護理產品組合。該公司提供預混合靜脈注射藥物和注射藥物組合，以滿足患者的需求。

門診手術中心、聘用醫生網路、兩家 HMO 和 15 家醫院均屬於 McLaren Healthcare 的一部分。醫療保健認證聯合委員會 (JCAHO) 和社區健康認證計劃 (CHAP) 均對麥克拉倫的家庭輸液服務進行了認證。

新興市場的主要發展

2022 年 4 月，AméricSource Bergon (AB) 啟動了一項計劃，幫助醫院和健康系統推出家庭輸液服務線。這將加強家庭輸液治療的專案策略、業務運作和物流。
2021 年 8 月，一家專門從事家庭輸液的新公司 HealthIV推出，以抑制脫水和宿醉。
2021年11月，醫院臨床血液腫瘤研究所（ICMHO）針對固態器官癌症患者啟動了免疫治療家庭輸液計畫和免疫治療。進行定期檢查、在患者家中給藥並提供健康教育。

The home infusion therapy market is anticipated to grow at a steady pace throughout the forecast period. Home infusion is just one of the many pharmaceutical treatments that are generally offered to patients in their homes as outpatient care. The bulk of these medications must be provided via a needle or catheter, a process known as an infusion; however, some can also be given intramuscularly, epidurally, or using self-injectable devices. Multiple associated benefits of home infusion therapy coupled with the increasing immobility disorders are major growth drivers in the home infusion therapy market. Moreover, the higher rate of hospital-acquired infections and government regulation to encourage home therapy are further contemplated to boost the home infusion therapy market.

Multiple Associated Benefits of Home Infusion Therapy

Home infusion therapy offers a wider range of benefits to patients that encourage its adoption and thereby boost the home infusion therapy market. Studies demonstrate that patients are highly satisfied with home infusion therapy and that clinical results are more positive at home than in inpatient hospital settings. Depending on an individual's healthcare plan, it can be less expensive than receiving the same service at a hospital or clinic. Moreover, with 78% of customers indicating they would be very or somewhat inclined to employ alternative types of treatment, such as a clinician visiting the home, according to EverNorth Health Services, there has been an increase in the demand for more flexibility and choice in how care is given in recent years. The patients' inclination towards home care coupled with associated benefits is contemplated to propel the home infusion therapy market.

Increasing Immobility Disorders

The increasing cases of immobility disorders restraining physical movement indicate the growing demand for home infusion therapy. For instance, there are 1.3 billion persons who are severely disabled. This equates to 1 in 6 of us, or 16% of the world's population as per WHO updates in March 2023. According to the WHO, Accessible and inexpensive transit is 15 times more difficult to find for people with disabilities than it is for people without impairments. Therefore, these immobility disorders are expected to positively impact the home infusion therapy market as it offers a convenient at-home setting to the patients.

Need for Reducing Stays at Hospital

Numerous infections occur when a person stays longer at the hospital and home infusion therapy helps to reduce the infections acquired from the hospitals. According to the WHO, Seven patients in high-income nations and 15 patients in low- and middle-income countries are expected to contract at least one healthcare-associated infection (HAI) during their hospital stay per 100 patients in acute-care hospitals. Every ten people who are impacted will die as a result of their HAI, on average. Newborns and those in critical care are particularly vulnerable and the WHO 2022 study finds that over half of all instances of sepsis with organ failure are treated in adult intensive-care units and about one in four hospital-treated sepsis cases are related to medical care. These hospital-acquired infections pose a problem and therefore encourage the adoption of the home infusion therapy market.

Opportunities in the Market

The growth drivers mentioned above indicate an immense opportunity for the home infusion therapy market. Moreover, government regulations are also providing a growth opportunity in the home infusion therapy market. For instance, in 2021, the Centres for Medicare & Medicaid Services (CMS) passed new regulations that increased the coverage of home infusion therapy to cover a variety of related nursing and monitoring services in addition to the treatment itself. Moreover, Eitan Medical launched a new cutting-edge connected infusion multi-therapy ambulatory infusion system named Avoset™ to transform post-acute care and speciality infusion therapy. Additionally, the approvals of home infusion therapy by the authorities further propel the home infusion therapy market thereby providing an entrance opportunity. For instance, home infusion of anticancer therapy was approved by the ASCO board of directors in June 2020.

Restraints in the Market

There are a few complexities that are supposed to restrain the home infusion therapy market. For example, home infusion pharmacies, patients, doctors, hospital discharge planners, health insurance, and other parties must work closely together to complete the procedure because it can be a complex ecology. Disconnected data poses a significant problem because there are so many parties involved and it can lead to a variety of prescribing, administering, and/or coding problems. For instance, the physician normally submits prior authorization requests and prescription claims, but they go through the plan separately.

North America is projected to Grow Significantly

The North American region is anticipated to hold a significant share of the home infusion therapy market during the forecasted period. Various factors attributed to such a share are increasing immobility disorders, chronic diseases such as cancer, and the aging population along with the favorable government regulations to encourage home infusion therapy. For instance, 12.1 percent of adult U.S. citizens have a mobility impairment that makes walking and climbing stairs extremely difficult and 12.8 percent of adults in the United States struggle greatly with concentration, memory, and decision-making as per the recent CDC data. Moreover, the market players such as Baxter, and Braun Melsungen AG are further expected to propel the home infusion therapy market in the region.

Home Infusion Therapy Market Players

Baxter International is a US-based healthcare company with a portfolio including acute, nutritional, renal, hospital, and surgical care products. The company provides a portfolio of intravenous premixed medication and injectable drugs that are ready to fill patients' needs.

Ambulatory surgery centers, employed physician networks, two HMOs, and 15 hospitals are all part of McLaren Health Care. The Joint Commission (JCAHO) and the Community Health Accreditation Programme (CHAP) have both granted accreditation to McLaren's home infusion service.

Key Market Developments

In April 2022, AmericsourceBergon (AB) launched a program designed to help hospitals and health systems to launch home infusion service lines. It serves to strengthen program strategy, business operations, and logistics in home infusion therapy.
In August 2021, HealthIV, a new company focused on home infusion was launched to curb dehydration and hangovers. The company has a digital platform that enables users to book an online appointment for a nurse to come to the home for home infusion therapy.
In November 2021, The Hospital Clinic Haematology and Oncology Institute (ICMHO) launched an immunotherapy home infusion program for solid organ cancer patients and immunotherapy treatment. It carries out periodical lab tests, administers drugs at patients' homes, and health education.

Segmentation:

By Product

Infusion Pump Sets
Accessories and Consumables

By Application

Total Parenteral Nutrition
Anti-infective Therapy
Enteral Nutrition
Hydration Therapy
Chemotherapy
IVIg/Specialty Pharmaceuticals
Other Applications

By Route of Administration

Intramuscular
Subcutaneously
Epidural

By Geography

North America
- United States
- Canada
- Mexico

South America
- Brazil
- Argentina
- Others

Europe
- United Kingdom
- Germany
- France
- Spain
- Others

The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Others

Asia Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Thailand
- Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. HOME INFUSION THERAPY MARKET, BY PRODUCT

5.1. Introduction
5.2. Infusion Pump Sets
5.3. Accessories and Consumables

6. HOME INFUSION THERAPY MARKET, BY APPLICATION

6.1. Introduction
6.2. Total Parenteral Nutrition
6.3. Anti-infective Therapy
6.4. Enteral Nutrition
6.5. Hydration Therapy
6.6. Chemotherapy
6.7. IVIg/Specialty Pharmaceuticals
6.8. Other Applications

7. HOME INFUSION THERAPY MARKET, BY ROUTE OF ADMINISTRATION

7.1. Introduction
7.2. Intramuscular
7.3. Subcutaneously
7.4. Epidural

8. HOME INFUSION THERAPY MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others